A new study shows how bacteria administered to foals via feeding tubes trigger a response in respiratory immune cells.
Translational results bolster confidence as Phase III trial for IMNN-001 in advance epithelial ovarian cancer gets underway.
CERo Therapeutics Holdings ( ($CERO) ) has shared an update. On September 22, 2025, CERo Therapeutics Holdings updated its corporate presentation, ...
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second ...
IMNN-001 continues to show a favorable safety profile.
Understanding the intricate workings of a chicken's gastrointestinal tract is crucial for optimising their health and ...
Working unconventional hours disrupts the body’s internal clock, which in turn affects the immune system and increases people ...
Explore how adaptive immunity influences Alzheimer’s disease, its impact on disease progression, and potential therapeutic ...
Immunotherapy has transformed the treatment of cancer, yet many patients do not have response or lasting benefit. Strategies ...
The NF-kB inhibitors market is poised for growth driven by the increasing prevalence of cancer, autoimmune, and inflammatory diseases where NF-kB plays a central role. Additionally, the expected ...
The NF-κB inhibitors market is poised for growth driven by the increasing prevalence of cancer, autoimmune, and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback